围术期老年心脏手术患者术后发生认知功能障碍及相关危险因素的临床观察性研究

注册号:

Registration number:

ChiCTR2400093822 

最近更新日期:

Date of Last Refreshed on:

2024-12-12 11:21:00 

注册时间:

Date of Registration:

2024-12-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

围术期老年心脏手术患者术后发生认知功能障碍及相关危险因素的临床观察性研究

Public title:

Clinical observational study of postoperative cognitive dysfunction and related risk factors in elderly patients undergoing perioperative heart surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围术期老年心脏手术患者术后发生认知功能障碍及相关危险因素的临床观察性研究

Scientific title:

Clinical observational study of postoperative cognitive dysfunction and related risk factors in elderly patients undergoing perioperative heart surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡蝶 

研究负责人:

王长明 

Applicant:

Hu Die 

Study leader:

Wang Changming 

申请注册联系人电话:

Applicant telephone:

+86 198 1898 6238

研究负责人电话:

Study leader's
telephone:

+86 177 0248 6100

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2432584911@qq.com

研究负责人电子邮件:

Study leader's E-mail:

TeamWangCM@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省沈阳市沈河区文艺路33号

研究负责人通讯地址:

辽宁省沈阳市沈河区文艺路33号

Applicant address:

33 Wenyi Road,Shenhe District, Shenyang, Liaoning

Study leader's address:

33 Wenyi Road,Shenhe District, Shenyang, Liaoning

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

辽宁省人民医院

Applicant's institution:

Liaoning Provincial People's Hospital

研究负责人所在单位:

辽宁省人民医院

Affiliation of the Leader:

Liaoning Provincial People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)H057号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

辽宁省人民医院伦理委员会

Name of the ethic committee:

Ethics committee of Liaoning Provincial People’s Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-20 00:00:00

伦理委员会联系人:

郑凯

Contact Name of the ethic committee:

Zheng Kai

伦理委员会联系地址:

辽宁省沈阳市沈河区文艺路33号

Contact Address of the ethic committee:

33 Wenyi Road,Shenhe District, Shenyang, Liaoning

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 24016355

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

辽宁省人民医院

Primary sponsor:

Liaoning Provincial People's Hospital

研究实施负责(组长)单位地址:

辽宁省人民医院

Primary sponsor's address:

Liaoning Provincial People's Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

Shen yang

单位(医院):

辽宁省人民医院

具体地址:

辽宁省沈阳市沈河区文艺路33号

Institution
hospital:

Liaoning Provincial People's Hospital

Address:

33 Wenyi Road,Shenhe District, Shenyang, Liaoning

经费或物资来源:

Source(s) of funding:

none

研究疾病:

心脏手术  

Target disease:

Cardiac surgery

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

拟通过严谨的临床前瞻性观察性队列研究来探索围术期内老年心脏手术患者术后谵妄的发生率及相关的危险因素以指导临床进行相关干预以降低心脏手术患者术后谵妄的发生率。  

Objectives of Study:

It is intended to explore the incidence of postoperative delirium and related risk factors in elderly patients with cardiac surgery in the perioperative period through rigorous clinical prospective observational study,so as to guide clinical intervention to reduce incidence of postoperative delirium in patients with cardiac surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有语言,听觉能力障碍的患者; 2.无法完成评估的患者; 3.有严重精神疾病的患者(精神分裂症,癫痫,帕金森病,阿尔兹海默症等); 4.使用精神类药物的患者; 5.急诊患者; 6.有酗酒史,吸毒史的患者; 7.曾经发生过谵妄的患者; 8.非首次心脏手术的患者; 9.透析患者; 10.肝功能B-C级的患者; 11.呼衰需氧疗的患者; 12.脑血管病史的患者(脑梗,脑出血史)。

Exclusion criteria:

1. Patients with language and hearing impairments; 2. Patients who are unable to complete the assessment; 3. Patients with severe mental illness (schizophrenia, epilepsy, Parkinson's disease, Alzheimer's disease, etc.); 4. Patients using psychotropic drugs; 5. Emergency patients; 6. Patients with a history of alcoholism and drug abuse; 7. Patients who have had delirium in the past; 8. Patients who are not the first time to undergo cardiac surgery; 9. Dialysis patients; 10. Patients with liver function grade B-C; 11. Patients on respiratory and aerobic therapy; 12. Patients with a history of cerebrovascular disease (cerebral infarction, history of cerebral hemorrhage).

研究实施时间:

Study execute time:

From 2024-12-20 00:00:00 To 2025-12-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-20 00:00:00 To 2025-12-20 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

240

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

辽宁省人民医院 

单位级别:

三甲 

Institution
hospital:

Liaoning Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

谵妄发生率

指标类型:

主要指标

Outcome:

Incidence of delirium

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛程度

指标类型:

次要指标

Outcome:

Pain level

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Hospital stays

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后拔管时间

指标类型:

次要指标

Outcome:

Postoperative extubation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU监护时间

指标类型:

次要指标

Outcome:

ICU monitoring time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 89 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后,中国临床试验注册中心(www.chictr.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the end of the study ,China trial registration central(www.chictr.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ReaMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-12 11:20:38